Conclusion:
Our study demonstrates that F-araA PK does not predict HCT outcome in patients with high-risk TM. NT5E promoter polymorphism could be a predictive biomarker in F-araA based HCT setting in TM; however, extensive functional studies are warranted to validate the clinical utility of this finding.